Ten Years of Percutaneous Pulmonary Valve Implantation in Australia and New Zealand

Lawley, Claire M.; Tanous, David; O’Donnell, Clare; Anderson, Benjamin; Aroney, Nicholas; Walters, D.; Shipton, S.; Wilson, William; Celermajer, David S.; Roberts, Philip A.

doi:10.1016/j.hlc.2022.07.008

Cited by 1 publication

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Longterm follow-up revealed that the majority of bioprosthetic pulmonary valves (including domestic VenusP-valves) without infective endocarditis may still retain satisfactory function even after more than 8-10 years of usage. 11,61 Once a valve fails (stenosis or regurgitation), further TPVR or surgical valve replacement is required.…”

Section: Failure Of the Bioprosthetic Valvementioning

confidence: 99%

“…The process of valve deterioration may occur gradually after TPVR because the pulmonary circulation blood flow shear force and flow rates are lower than those of the systemic circulation. Long‐term follow‐up revealed that the majority of bioprosthetic pulmonary valves (including domestic VenusP‐valves) without infective endocarditis may still retain satisfactory function even after more than 8–10 years of usage 11,61 . Once a valve fails (stenosis or regurgitation), further TPVR or surgical valve replacement is required.…”

Section: Prevention and Treatment Of Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

2024 Statement from Asia expert operators on transcatheter pulmonary valve replacement

Pan,

Zhou,

Hijazi

et al. 2024

Cathet Cardio Intervent

View full text Add to dashboard Cite

Transcatheter pulmonary valve replacement (TPVR), also known as percutaneous pulmonary valve implantation, refers to a minimally invasive technique that replaces the pulmonary valve by delivering an artificial pulmonary prosthesis through a catheter into the diseased pulmonary valve under the guidance of X‐ray and/or echocardiogram while the heart is still beating not arrested. In recent years, TPVR has achieved remarkable progress in device development, evidence‐based medicine proof and clinical experience. To update the knowledge of TPVR in a timely fashion, and according to the latest research and further facilitate the standardized and healthy development of TPVR in Asia, we have updated this consensus statement. After systematical review of the relevant literature with an in‐depth analysis of eight main issues, we finally established eight core viewpoints, including indication recommendation, device selection, perioperative evaluation, procedure precautions, and prevention and treatment of complications.

show abstract

Section: Failure Of the Bioprosthetic Valvementioning

confidence: 99%

Section: Prevention and Treatment Of Complicationsmentioning

confidence: 99%